About
GPCR-targeted Drugs
Areas of Focus
Categories
Small Molecule PharmaceuticalSan Diego & Southern California
Team (28)
Aaron Mishel
Aaron Mishel
Escient Pharmaceuticals
team_member
Aaron Mishel
Aaron Mishel
Escient Pharmaceuticals
team_member
Alex Dorenbaum
Alex Dorenbaum, MD
Escient Pharmaceuticals
team_member
Andrew Schwab
Andrew Schwab
Escient Pharmaceuticals
team_member
Ben Auspitz
Ben Auspitz
Escient Pharmaceuticals
team_member
Bryan L
Bryan L. Roth, MD, PhD
Escient Pharmaceuticals
team_member
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
9
As Collaborator
0
Total Enrollment
639
By Phase
PHASE1: 3PHASE2: 3PHASE4: 2
By Status
COMPLETED: 7TERMINATED: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT06645704Lead Sponsor
An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration
PHASE1Completed
10 participants
Started: Oct 1, 2024 · Completed: Dec 10, 2024
NCT06144424Lead Sponsor
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
PHASE2Completed
32 participants
Started: Oct 25, 2023 · Completed: Jul 31, 2024
NCT06077773Lead Sponsor
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria
PHASE2Terminated
113 participants
Started: Sep 25, 2023 · Completed: Jan 16, 2025
NCT06050928Lead Sponsor
Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria
PHASE1Completed
33 participants
Started: Aug 30, 2023 · Completed: Oct 22, 2024
NCT05525520Lead Sponsor
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
PHASE2Completed
62 participants
Started: Oct 6, 2022 · Completed: Sep 5, 2024
Locations (1)
Headquarters
San Diego, CA, United States
Map
Loading map...